# 21 U.S.C. 356b Reports of postmarketing studies

21 U.S.C. 356b Reports of postmarketing studies, “Reports of postmarketing studies”, is a U.S. Code section of [Part A—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb97-754b-b68a-a66a473f5a0d); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f06c-ccea-769f-b60a-251047e97ffa>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f06c-cb65-7672-8fda-c39517ff08c0) › [Chapter 9—Federal Food, Drug, and Cosmetic Act](https://ontology.bommaritollc.com/id/01a0f06c-cb91-72e0-858b-060e8c845f23) › [Subchapter V—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb96-7040-b454-c8f18e0e95cb) › [Part A—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb97-754b-b68a-a66a473f5a0d)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [usc-section 21 U.S.C. 356b](https://ontology.bommaritollc.com/id/01a0f06c-cceb-7622-a6eb-e8a88badc964)
- `eli:cites`:
  - [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f06c-cb65-7672-8fda-c39517ff08c0)
  - [21 U.S.C. 356 Expedited approval of drugs for serious or life-threatening diseases or conditions](https://ontology.bommaritollc.com/id/01a0f06c-cce5-749b-bd0a-9561cfcbbfe8)
  - [21 CFR 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.](https://ontology.bommaritollc.com/id/01a0f094-c4e5-76cd-b2d9-17a3b02eef62)
  - [21 CFR 601.41 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.](https://ontology.bommaritollc.com/id/01a0f094-cb3c-740a-89ba-0b781f56e82c)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapV-partA-sec356b](https://ontology.bommaritollc.com/id/01a0f06c-ccea-769f-b60a-250f016ff505)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f06c-d152-71b4-87f1-71d6e9d09d75)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0d2-2d49-7745-9cd9-e5a39614134b)
  - [evidence from https://www.govinfo.gov/link/uscode/21/356b?type=usc&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f15-fe25-72f2-b601-7ca2796971bb)
- `schema:isPartOf`: [Part A—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb97-754b-b68a-a66a473f5a0d)
- `schema:legislationIdentifier`: 21 U.S.C. 356b
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [U.S. Code section](https://ontology.bommaritollc.com/vocab/leg/uscSection)
- `schema:name`: Reports of postmarketing studies
- `schema:url`: [https://www.govinfo.gov/link/uscode/21/356b?type=usc&year=mostrecent&link-type=details](https://www.govinfo.gov/link/uscode/21/356b?type=usc&year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 U.S.C. 356b Reports of postmarketing studies

## Elsewhere

- [Official page](https://www.govinfo.gov/link/uscode/21/356b?type=usc&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapV-partA-sec356b) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Rules made under it (4; `eli:based_on`):
  - [21 CFR Part 230—Certification and postmarketing reporting for designated medical gases (Eff. 12-18-25)](https://ontology.bommaritollc.com/id/01a0f094-b846-700a-99cf-b5ff460516cd)
  - [21 CFR Part 314—Applications for FDA approval to market a new drug](https://ontology.bommaritollc.com/id/01a0f094-b84d-7031-b149-cb632d656858)
  - [21 CFR Part 601—Licensing](https://ontology.bommaritollc.com/id/01a0f094-b882-764a-a051-b44410b6e848)
  - [21 CFR Part 740—Cosmetic product warning statements](https://ontology.bommaritollc.com/id/01a0f094-b88d-71bd-8d90-cd0e83729420)
- Amended by (3; `eli:amends`):
  - [Pub. L. 107-188](https://ontology.bommaritollc.com/id/01a0edf4-a7b5-702d-b34b-3ecf84f32c4c)
  - [Pub. L. 112-144](https://ontology.bommaritollc.com/id/01a0f06a-a3b6-70e5-8204-79bb2755f506)
  - [Pub. L. 117-328](https://ontology.bommaritollc.com/id/01a0edf4-a3b3-73ad-8a5b-366dfc33cea1)
- Cited by (1; `eli:cites`):
  - [21 U.S.C. 331 Prohibited acts](https://ontology.bommaritollc.com/id/01a0f06c-cc92-7163-972f-ca345be44724)
- Its changes, from (1; `eli:changes`):
  - [Pub. L. 105-115](https://ontology.bommaritollc.com/id/01a0f06c-d29f-7443-a96a-3934363a8187)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f06c-ccea-769f-b60a-251047e97ffa.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f06c-ccea-769f-b60a-251047e97ffa.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f06c-ccea-769f-b60a-251047e97ffa.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f06c-ccea-769f-b60a-251047e97ffa)
Cite as: 21 U.S.C. 356b Reports of postmarketing studies. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f06c-ccea-769f-b60a-251047e97ffa
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
